Bio Integrates 2022 Track 2
How do we protect, progress and pivot our products for maximal value?
Welcome and opening remarks
A fireside chat with Andreas Wallnoefer
A fireside chat with Ruth McKernan CBE
Making your product fit for purpose
How are you responding to the increasing interest, pressure, regulation, and legislation around the ethics, provenance, and sustainability of products? Are you ready? Can you see market opportunities?
NAZNEEN RAHMAN CBE | Chief Executive Officer and NED| YewMaker and AstraZeneca
JOHN CLACK | VP, Manufacturing | COMPASS Pathways
KRZYSZTOF POTEMPA | Founder and CEO | BRAINCURES
LISA DITTMAR | Net Zero and Sustainable Supply Chain Lead | NHS England
RACHEL GRIFFITHS | Director, Technical Services | PCI Pharma Services
DAVE ENNIS |Vice President of Chemical Development | AstraZeneca
Protect at all costs
The costs of protecting your IP can ramp up rapidly. How can you plan your IP strategy efficiently and cost-effectively?
JAMES FRY | Partner and Head of Life Sciences | Mills & Reeve
AHMED BOUZIDI | Vice-President Biotech | ProductLife Group
EMMANUELLE ASTOUL | Head of Licensing | Transine Therapeutics
RAMINDERPAL SINGH | Chief Executive Officer and co-Founder | Incubate.bio Ltd
MARC WILKINSON | Partner, Patent and Trade Mark Attorney | J A Kemp
CARL EDWARDS | Head of IP & Commercial and LD3 Manager | University of Leicester
Finding the right outsourcing partners to help develop and scale your products is critical to milestones and budgets. How can we ensure we are working with the right partners at the right time?
PAUL BRANTHWAITE | Senior Partner & Client Liaison | tranScrip
MAURA MCARDLE | Head Of Business Development (Europe) | SGS QuayPharma
PETER MACLENNAN | Chief Executive Officer | Tailored Clinical Research Solutions
STEVE TRIM | Founder / Chief Scientific Officer | Venomtech
CLAIRE PATTERSON | Senior Principal Scientist | SEDA Pharmaceutical Development Services
BODIL VAN NIEL | Director of Chemistry | Charles River Laboratories
ALAN LAHAISE | Vice President, Business Development, Manufacturing and EMEA Clinical Services | PCI Services
Been there, done that
Success stories from those who have felt the fire at their feet, bridged the valley of death, scaled and sold their companies.
RICHARD WEAVER | Senior Vice President, Pre-clinical Development | Sygnature Discovery
JO CRAIG | Senior Vice President CMC | NeRRe Therapeutics
MARK MCHALE | Chief Scientific Officer | Oak Hill Bio
JOHN VON BENECKE | Chief Executive Officer | Locate Bio
NICK SMITH | Site Director, Alderley Park |
Charles River Laboratories
CRAIG FOX | Operating Partner (Lifesciences) | Oxford Science Enterprises
Fuelling the genetic medicine revolution
Nucleic acid (mRNA and DNA) vaccines aren’t necessarily new, but recent outcomes during the COVID pandemic are stimulating a renaissance in the wider biopharmaceutical industry as drug manufacturers turn their attention to issues such as speed-to-market, faster scale-up and, of course, safety. For commercial success, however, key challenges such as long lead times and high capital costs need to be overcome. Novel technologies such as synthetic vectors are not only able to target genes with a size and complexity that current technologies can’t, they may also offer solutions to current capacity and supply chain constraints. So, are the days of fermentation over? Is this a new era of global-scale mass production for cold-chain-free gene therapies and, perhaps most importantly from a regulatory standpoint, are these advanced therapeutics biological anymore?
JONATHAN APPLEBY | Chief Scientific Officer | Cell and Gene Therapy Catapult
HELEN HORTON | Chief Research Officer | Touchlight
KEITH WILLIAMS| Co-founder Managing Director | Phenotypeca
JOSHUA BLIGHT | Chief Executive Officer & Co-Founder | Baseimmune
KARIN SCHMITT | Chief Business Officer | Mogrify
BAKUL GUPTA | Chief Executive Officer and Co-founder | ImmTune Therapies